Patients with small or greater amounts of myocardial injury had significantly increased risk for death
WEDNESDAY, June 10, 2020 (HealthDay News) — Among patients hospitalized with COVID-19, troponin I elevation is associated with an increased risk for death, according to a study published online June 8 in the Journal of the American College of Cardiology.
Anuradha Lala, M.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues describe the degree of myocardial injury and associated outcomes among 2,736 patients with COVID-19 admitted to one of five Mount Sinai Health System hospitals in New York City between Feb. 27 and April 12, 2020. Patients had troponin I measured within 24 hours of admission.
Patients had a median age of 66.4 years, and 59.6 percent were men. The researchers found that cardiovascular disease, including coronary artery disease, atrial fibrillation, and heart failure, as well as hypertension and diabetes, were more prevalent among patients with higher troponin concentrations. Overall, 18.5 percent of patients died during hospitalization. Thirty-six percent of patients had elevated troponin concentrations. Even small amounts of myocardial injury (e.g., troponin I, 0.03 to 0.09 ng/dL) were significantly associated with an increased risk for death (adjusted hazard ratio, 1.75), and greater amounts of myocardial injury (e.g., troponin I >0.09 ng/dL) were significantly associated with a higher risk for death (adjusted hazard ratio, 3.03) after adjustment for disease severity and relevant clinical factors.
“Even small amounts of heart injury could be linked to a pronounced risk of death, and COVID-19 patients with a history of cardiovascular disease are more likely to have myocardial injury when compared to patients without heart disease,” Lala said in a statement.
Several authors disclosed ties to biopharmaceutical and medical technology companies, including Clinithink, which developed the natural language processing software used in the study.
Copyright © 2020 HealthDay. All rights reserved.